Navigation Links
Singapore scientists expose molecular secrets of bile duct cancers from different countries

SINGAPORE - A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer. The team, led by Professors Teh Bin Tean, Patrick Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used advanced DNA sequencing technologies to map the complete repertoire of human genes disrupted in cholangiocarcinoma.

2. The team's findings may lead to new cholangiocarcinoma treatments, and have shed light on some of the oldest questions in cancer research. The group is also affiliated with the Genome Institute of Singapore and the Cancer Science Institute in Singapore. This work was published online today in the scientific journal Nature Genetics.

3. Cholangiocarcinoma (CCA), is a cancer involving uncontrolled growth of the bile ducts, the part of the liver that drains bile into the intestine. In most countries, CCA is considered a rare cancer, but the incidence of CCA is rising worldwide and in certain countries such as the North East of Thailand and neighbouring Laos, CCA is already widespread due to patients in this region being exposed to liver flukes. Other potential causes of CCA include bile duct inflammation, congenital cysts, hepatitis, and the presence of liver stones. Patients diagnosed with CCA have a dismal prognosis as the disease is considered incurable, with a 5-year survival rate of 5%.

New Potential Avenues for Treatment

4. By studying CCAs from Singapore, Thailand and Romania, the team identified several genes that were repeatedly disrupted in order for CCA to develop. Importantly, the cellular pathways controlled by these genes have suggested new potential avenues to treat CCA. One such gene identified, BAP1, participates in the unpacking of DNA, and drugs targeting this process (called "chromatin modifier drugs") are being developed. Prof Teh said "While further research needs to be done, this may pave the way for identifying which bile-duct cancer patients may benefit from chromatin-modifier drugs."

5. Findings from the study have also deepened our basic understanding of how cancer develops. Prof Rozen said "A poorly-understood question in cancer research is whether different carcinogens, applied to the same cancer type, will cause disruptions in the same sets of genes, or if different carcinogens will cause different type of genes to be disrupted".

6. The team reasoned that CCAs could be used to answer these questions, as these cancers are caused by different carcinogenic exposure in different parts of the world. They found that while CCAs from Thailand, Singapore and Romania appeared very similar under the conventional microscope, at the molecular level they were in fact very different. This provides one of the first key pieces of evidence that different types of carcinogen exposures, although acting on the same type of tissue, are associated with disruptions in different sets of genes. Such findings have practical applications as well. Prof Tan said "Based on these results, it may be possible to investigate a patient's cancer and by looking at the types of disrupted genes, infer what caused the cancer." Such information would have major implications for cancer prevention efforts.

7. This most recent work is the latest in a series of high-profile papers from the Singapore team applying genomic analysis to cancers prevalent in Asia. In August, the same team reported their findings on a specific type of urinary tract cancer prevalent in Taiwan, which was caused by a carcinogen found in certain herbal remedies.

Invitation to join leading International Cancer Genome Consortium

8. The success of the team has not gone unnoticed by the international community. In October, the team of Professors Teh, Tan and Rozen was invited to join the International Cancer Genome Consortium (ICGC), a multi-national consortium composed of the world's leading scientists in cancer genomics, which aims to analyze over 50 different types of cancer. The Singapore team will take the lead in organizing the ICGC CCA sequencing program. "The ICGC Executive committee welcomes the participation of Singapore with great enthusiasm. The cholangiocarcinoma project will fit an important gap in the ICGC list of cancer types and the Singapore team has a track record of proven expertise and experience in this field", said Dr Tom Hudson, Chair of ICGC Executive Committee.

9. To-date, the Singapore team has raised funds from charities including a million dollar donation from a patient, and research institutions in Singapore to support the ICGC effort. Prof Teh concluded "This will be first time that Singapore has participated in such a large international cancer consortium. We will do our utmost to make this international effort a success but our greatest hope is that our findings will ultimately benefit cancer patients worldwide"


Contact: Rachel Tan

Related biology news :

1. Singapore scientists discover new RNA processing pathway important in human embryonic stem cells
2. Physiotherapy in Singapore Clinic Urbanrehab Pte Ltd Announces the Opening of an Additional Location
3. Less haze in Singapore as the cause becomes clearer and more complex
4. Singapore research team identifies new drug target in deadly form of leukemia
5. First in the world - Singapore scientists discover genes responsible for cornea blindness
6. National Heart Centre Singapore develops worlds first human heart cell model
7. Singapore scientists find genes associated with glaucoma, a major cause of eye blindness
8. NUS launches new book on Singapores rainforests and new free digital nature archive
9. Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test
10. Animal welfare scientists reveal infrequent and inconsistent acceptance of existing data by EPA to satisfy endocrine disruptor testing requirements
11. 2 grants to UC Riverside boost scientists efforts in developing improved cowpea varieties
Post Your Comments:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... Muncie, IN (PRWEB) , ... November 24, 2015 , ... ... its newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to ... in the last few years. Many AMA members have embraced this type of racing ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology: